公开(公告)号：US20240110244A1

公开(公告)日：2024-04-04

申请号：US17768601

申请日：2020-10-08

Applicant: GENCURIX INC.

Inventor： Sang Rae CHO ,  Young Ho MOON ,  Jin Il HAN

IPC: C12Q1/6886

CPC classification number: C12Q1/6886 ,  C12Q2600/154

Abstract: The present invention relates to a composition, a kit, a nucleic acid chip and a method which allow the diagnosis of liver cancer by detecting methylation levels of CpG sites of any one or more genes selected from the group consisting of FAM110A, FAR1, VIM, LDHB, LIPE, INAFM1, ATL1, CELF6, MTHFD2, PAK1, NXPE3, SLC25A36 and VANGL2. The present invention enables accurate and rapid diagnosis of liver cancer, and also enables early diagnosis.

公开(公告)号：US20200071768A1

公开(公告)日：2020-03-05

申请号：US16462655

申请日：2017-11-21

Applicant: GENCURIX INC.

Inventor： Sang Rae CHO ,  Young Ho MOON ,  Jin Il HAN ,  Young Kee SHIN

IPC: C12Q1/6886

Abstract: The present invention relates to a method for predicting the prognosis of a breast cancer patient. More specifically, to provide information needed to predict the prognosis of a breast cancer patient, the method for predicting the prognosis of breast cancer including the following steps of the present invention comprises: (a) obtaining a biological sample from a breast cancer patient; (b) measuring the mRNA expression level of matrix metallopeptidase 11 (MMP11) and the mRNA expression level of cluster of differentiation 2 (CD2) from patient information or the sample of step (a); (c) normalizing the gene mRNA expression levels selected and measured in step (b); and (d) predicting the prognosis of breast cancer by combining the gene expression levels normalized in step (c), wherein overexpression of the MMP11 indicates a bad prognosis, and overexpression of CD2 indicates a good prognosis.The method of the present invention has an effect of being capable of more accurately predicting the future prognosis of metastasis, recurrence, or metastatic recurrence in breast cancer patients, and in particular, has a very excellent ability to predict the prognosis of HER2-type breast cancer, the prognosis of which is very poor, and thus can be usefully used to provide clues for the direction of future treatment of breast cancer.

公开(公告)号：US20180216199A1

公开(公告)日：2018-08-02

申请号：US15938633

申请日：2018-03-28

Applicant: GENCURIX INC.

Inventor： Sang Rae CHO ,  Young Ho MOON ,  Jin Il HAN ,  Young Kee SHIN

IPC: C12Q1/6886

CPC classification number: C12Q1/6886 ,  C12Q1/68 ,  C12Q2600/118 ,  C12Q2600/158

Abstract: The present invention relates to a method of predicting the effectiveness of chemotherapy in a breast cancer patient, and more particularly, to a method for predicting the effectiveness of chemotherapy by measuring the expression levels of genes for predicting prognosis of breast cancer and a standard gene in a biological sample obtained from the breast cancer patient, and a method for predicting the difference between a patient group having a high effectiveness of chemotherapy and a patient group having a low effectiveness of chemotherapy.Therefore, the method of the present invention can accurately predict the effectiveness of chemotherapy for the breast cancer patient and can be used for the purpose of presenting clues about the direction of breast cancer treatment in the future.

公开(公告)号：US20180216198A1

公开(公告)日：2018-08-02

申请号：US15938331

申请日：2018-03-28

Applicant: GENCURIX INC.

Inventor： Sang Rae CHO ,  Young Ho MOON ,  Jin Il HAN ,  Young Kee SHIN

IPC: C12Q1/6886

Abstract: The present invention relates to a method of predicting the effectiveness of chemotherapy in a breast cancer patient, and more particularly, to a method for predicting the effectiveness of chemotherapy by measuring the expression levels of genes for predicting prognosis of breast cancer and a standard gene in a biological sample obtained from the breast cancer patient, and a method for predicting the difference between a patient group having a high effectiveness of chemotherapy and a patient group having a low effectiveness of chemotherapy.Therefore, the method of the present invention can accurately predict the effectiveness of chemotherapy for the breast cancer patient, and can be used for the purpose of presenting clues about the direction of breast cancer treatment in the future.